The University of New Mexico has begin recruiting 300 women to participate in a Phase III vaccine trial that aims to prevent infection with two strains of human papillomavirus linked to more than 70% of all cervical cancer cases, the Albuquerque Journal reports. The vaccine aims to prevent against infection by HPV16 and HPV 18 strains of the virus. Animal tests of a similar vaccine targeting only HPV16 showed it prevented 100% of HPV infections. The UNM vaccine trial site is one of several around the world that will test the vaccine among more than 10,000 women ages 15-25. Participants will receive three inoculations over a six-month period, and then be followed-up for signs of HPV in their blood or the presence of abnormal cells, which can be precancerous, in Pap tests. Cervical cancer is a common disease among HIV-positive women and is considered an AIDS-defining condition.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















